Date of event
Continuing Education Credits
Liver Cell Biology in Hepatic Diseases SIG
- Thiru Selvanantham, PhD
- Samar Ibrahim, MBChB, NASPGHAN-F
- Xavier S. Revelo, PhD
- Udayan Apte, PhD, DABT
- Petra Hirsova, PharmD, PhD
Mass Cytometry, also called CyTOF, is a novel technology that has revolutionized identification of different functional cell types in pathologies with heteronomous cell populations. Its use in liver pathophysiology has only begun and it holds a great promise determining cell-cell crosstalk in liver diseases. This webinar will focus on the basics of CyTOF technology and discuss its application in both basic and clinical liver research.
Thiru Selvanantham, PhD
Thiru Selvanantham, PhD is a Senior Product Manager for Fluidigm earned her PhD in immunology from the University of Toronto, with a focus on invariant natural killer T (iNKT) cell activation by pattern recognition receptors (NOD1 and NOD2) for bacterial products. She joined Fluidigm, based in Markham Canada, to develop new mass cytometry reagent and application products. As Senior Product Manager, Thiru is responsible for suspension mass cytometry platforms, including the CyTOF XT that was launched in 2021.
Dr. Selvanantham is the Senior Product Manager for suspension CyTOF instruments. During her PhD, she studied the boundary of the innate and adaptive immune system investigating NKT cells in bacterial infection models in mice. She has been published in the Journal of Immunology and Infection and Immunity. As a product applications scientist, she has developed immune profiling panels and conducted multi-site studies using high-parameter mass cytometry. She has presented and taught immunology courses for medical program and applied immunology master program at the University of Toronto. As Senior Product Manager, she is responsible for the life cycle of CyTOF XT and Helios and has presented at cytometry conferences.
Samar Ibrahim, M.B.Ch.B.
Samar Ibrahim, M.B.Ch.B is an Associate Professor of Pediatrics and Physiology, Division of Pediatric Gastroenterology and Hepatology at Mayo Clinic. Dr. Ibrahim is a pediatric transplant hepatologist and a physician scientist. Dr. Ibrahim is the Principal Investigator of the NIH-funded lipotoxicity and liver inflammation laboratory at Mayo Clinic. She studies the mechanism of liver injury and inflammation in nonalcoholic steatohepatitis (NASH), with the goal to identify novel biomarkers and mechanism-based therapeutic targets. Her recently published work identified the vascular adhesion molecule 1 (VCAM1) as a potential novel therapeutic target in NASH. Dr. Ibrahim and her research team have examined the role of extracellular vesicles as biomarkers, as well as mediators of intercellular communication in NASH pathobiology. They recently defined the role of integrin β1-enriched extracellular vesicles in NASH. She is the director of the Pilot and Feasibility program at the Digestive Disease Center at Mayo Clinic and moderates the center weekly Scientific Seminar Series. Dr. Ibrahim has served on NIDDK study sections, as well as a reviewer for international funding agencies.
Dr. Ibrahim serves as the Medical Director of the Pediatric Liver Transplant Program at Mayo Clinic and is interested in studying factors responsible for late liver graft dysfunction, as well as developing models that better predict the acuity of the pediatric liver transplant candidate on the wait list. Dr. Ibrahim has mentored numerous medical students, residents, and postdoctoral fellows. She is an associate editor for HEPATOLOGY and a steering committee member of the AASLD pediatric special interest group. She is a NASPGHAN fellow and a member of the NASPGHAN hepatology committee and the SPLIT education and advocacy committees.
Xavier Revelo, PhD
Xavier Revelo, PhD is an Assistant Professor in the Department of Integrative Biology & Physiology and Center for Immunology at the University of Minnesota. His laboratory studies the role of the immune system and inflammation in the pathophysiology of cardio-metabolic diseases. Dr. Revelo has a broad background in metabolism, physiology, and immunology and expertise in metabolic inflammation. He trained in the field of immunometabolism where he studied immune mediators of insulin resistance. Since starting his laboratory in 2018, he leads NIH-funded research investigating the mechanisms by which immune cells promote cardio-metabolic diseases such as non-alcoholic fatty liver disease, insulin resistance, and heart failure.
Udayan Apte, PhD, DABT
Udayan Apte, PhD, DABT is a Professor in the Department of Pharmacology, Toxicology and Therapeutics at the University of Kansas Medical Center in Kansas City, Kansas. His areas of expertise include basic liver pathobiology with the focus on mechanisms of liver regeneration, drug-induced liver injury and liver cancer pathogenesis, role of nuclear receptors in liver biology and disease, signal transduction mechanisms involved in regulation of hepatocyte proliferation, biomarker discovery with focus on DILI and HCC.
Dr. Apte has served on the Membership Committee of AASLD and as a membership committee liaison to DILI SIG. Currently, he is a member of Liver Cell Biology SIG executive committee. He also serves on the Research Awards Committee of AASLD. Dr. Apte runs an NIH funded independent research program and is deeply involved in graduate education focused on liver toxicology. Dr. Apte serves on editorial boards on American Journal of Pathology, Toxicology and Applied Pharmacology. He serves as a senior associate editor for Scientific Reports and as an associate editor for BioMed Research International. He is a frequent reviewer for both NIH and non-NIH grants. He has published over 80 original research papers, several reviews and book chapters. He has also edited a book on basic mechanisms of liver regeneration published by Elsevier.
Petra Hirsova, PharmD, PhD
Petra Hirsova, PharmD, PhD is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic Rochester, MN. Dr. Hirsova received doctoral training from Charles University, Czech Republic, and Yale University, Connecticut. Subsequently she became a postdoctoral fellow at Mayo Clinic, where she later rose to the rank of Assistant Professor. She currently leads an independent research program focused on nonalcoholic fatty liver disease (NAFLD), especially as it relates to understanding the pathogenic mechanisms underlying the disease onset and progression, identifying druggable targets, and developing novel therapeutic strategies. Her research program has been supported by multiple funding mechanisms provided by the National Institute of Health (NIH), foundations, and the Mayo Clinic.
Dr. Hirsova serves as an editorial board member for HEPATOLOGY, the official journal of the American Association for the Study of Liver Diseases (AASLD). Dr. Hirsova has also held various leadership positions within the AASLD. She served as a member of the Inclusion and Diversity Committee. Currently, she serves on the steering committee of the NAFLD Special Interest Group (SIG), where she is responsible for educational activities and the steering committee of Liver Cell Biology SIG. Dr. Hirsova has served as a member of the AASLD Abstract Committee for NAFLD research since 2021. In addition, she is a member of the AASLD Research Award Committee. Outside of the AASLD, Dr. Hirsova reviews grants for Charles University, European Science Foundation, and NIH.